Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

HDAC inhibitors (HDACis) have been intensively studied for their roles and potential as drug targets in T-cell lymphomas and other hematologic malignancies. Bisthianostat is a novel bisthiazole-based pan-HDACi evolved from natural HDACi largazole. Here, we report the preclinical study of bisthianost...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yu-bo, Zhang, Yang-ming, Huang, Hong-hui, Shen, Li-jing, Han, Xiao-feng, Hu, Xiao-bei, Yu, Song-da, Gao, An-hui, Sheng, Li, Su, Ming-bo, Wei, Xiao-li, Zhang, Yue, Zhang, Yi-fan, Gao, Zhi-wei, Chen, Xiao-yan, Nan, Fa-jun, Li, Jia, Hou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976035/
https://www.ncbi.nlm.nih.gov/pubmed/34341512
http://dx.doi.org/10.1038/s41401-021-00728-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976035/
https://www.ncbi.nlm.nih.gov/pubmed/34341512
http://dx.doi.org/10.1038/s41401-021-00728-y

Ejemplares similares